Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 8/20 | 0.36 |
| ▸ | RAB9A | P51151 | 8/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 5/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.35 |
| ▸ | NTRK2 | Q16620 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | GFER | P55789 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL22807345 | 0.84 | NPC1 (0.43) | NPC1RAB9AKDM4ETDP1HKDC1 | |
| SCHEMBL22608654 | 0.81 | NPC1 (0.49) | NPC1RAB9AKDM4ETDP1HKDC1 | |
| SCHEMBL22807477 | 0.80 | HAO1 (0.41) | NTRK1NTRK2 | |
| SCHEMBL22608701 | 0.75 | HAO1 (0.35) | — | |
| SCHEMBL22608384 | 0.72 | NPC1 (0.33) | NPC1RAB9AKDM4EL3MBTL1ALDH1A1 | |
| SCHEMBL22608147 | 0.72 | RHEB (0.36) | KMT2A | |
| SCHEMBL22608396 | 0.71 | ITGB2 (0.39) | — | |
| SCHEMBL22807330 | 0.70 | IDH1 (0.31) | — | |
| SCHEMBL22608246 | 0.70 | NPC1 (0.32) | NPC1RAB9AKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL22608636 | 0.70 | ITGB2 (0.40) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230089374-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2023-03-23 | — | — | US | disclosed |
| US-20230088214-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2023-03-23 | — | — | US | disclosed |
| US-20230079913-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2023-03-16 | — | — | US | disclosed |
| US-11384055-B2 | Glycolate oxidase inhibitors for the treatment of disease | BIOMARIN PHARMACEUTICAL INC. (US) | 2022-07-12 | — | — | US | disclosed |
| EP-3986863-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BioMarin Pharmaceutical Inc. (US) | 2022-04-27 | — | — | EP | disclosed |
| CN-114258390-A | Glycolate oxidase inhibitors for disease treatment | 生物马林药物股份有限公司 | 2022-03-29 | — | — | CN | disclosed |
| US-20210171474-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2021-06-10 | — | — | US | disclosed |
| WO-2020257487-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2020-12-24 | — | — | WO | disclosed |
| CN-111788187-A | Glycolate oxidase inhibitors for disease treatment | 生物马林药物股份有限公司 | 2020-10-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230079913-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | XDH, PNPO, AGXT | NPC1 1158/4885RAB9A 3923/4885KDM4E 3645/4885 |
| US-20230088214-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | XDH, PNPO, AGXT | NPC1 1113/4885RAB9A 3978/4885KDM4E 3325/4885 |
| US-11384055-B2 | Glycolate oxidase inhibitors for the treatment of disease | XDH, PNPO, AGXT | NPC1 1158/4885RAB9A 3923/4885KDM4E 3645/4885 |
| US-20230089374-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | XDH, PNPO, AGXT | NPC1 1158/4885RAB9A 3923/4885KDM4E 3645/4885 |
| US-20210171474-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | XDH, PNPO, AGXT | NPC1 1158/4885RAB9A 3923/4885KDM4E 3645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.